Ipca Labs partners with MMV to co-develop novel antimalarial co-formulation

Ipca Laboratories Ltd. informed the exchanges that it has entered an agreement with a leading product development partnership, Medicines for Malaria Venture (MMV), to co-develop a novel antimalarial co-formulation named "Atoguanil".

Atoguanil, based on proprietary Ipca technology, contains the active pharmaceutical ingredients atovaquone and proguanil. Today, the manufacturing cost of atovaquone is believed to pose a barrier to widespread use of atovaquone-proguanil based products in malaria-endemic countries. Atoguanil has the potential to provide a lower cost alternative, making such products more accessible to people living in malaria-endemic countries for prophylaxis.

Ipca Laboratories Ltd is currently trading at Rs1,133.50 down by Rs5.3 or 0.47% from its previous closing of Rs1,138.80 on the BSE.

The scrip opened at Rs1,141 and has touched a high and low of Rs1,143.40 and Rs1,130 respectively. So far 1,03,446 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs14,388.98cr.

About Gosip4U

Gosip4U is the digital wing of india - India's leading media and communications group with its interests spanning across country.


Post a Comment

Please add comment